Minerva Neurosciences, IncNASDAQ: NERV

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

· Issued by Minerva Neurosciences, Inc via GlobeNewswire

Summary by 6ix AI

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, said its management will take part in the Wells Fargo Healthcare Conference and the 2026 Cantor Global Healthcare Conference, both in New York, NY.

Key details

  • Wells Fargo Healthcare Conference: Tuesday, September 8, one-on-one meetings with investors.
  • 2026 Cantor Global Healthcare Conference: Wednesday, September 9, a fireside chat (a moderated on-stage discussion) from 2:45 to 3:15 PM EDT, plus one-on-one meetings.
  • A live webcast will be available on the Minerva Neurosciences website, with a replay available approximately two hours after the events end and archived on the company's website.

6ix AI wrote this summary from the release below and checked it against the release.

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.

Wells Fargo Healthcare Conference
Date: Tuesday, September 8
Format: 1x1 meetings
Location: New York, NY

2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9
Format: Fireside chat and 1x1 meetings
Time: 2:45 – 3:15 PM EDT
Location: New York, NY

If you are interested in meeting with the Minerva team during the conferences, please reach out to your respective conference representative.

The live webcast can be accessed in the events section of the Minerva Neurosciences website HERE. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company's website.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company's website.

Contacts:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
[email protected]

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
[email protected]

Minerva Neurosciences, Inc on 6ix

Story so far

Earlier from Minerva Neurosciences

Later from Minerva Neurosciences

All Minerva Neurosciences news releases